325 related articles for article (PubMed ID: 21865537)
21. Lentiviral Gene Therapy for Artemis-Deficient SCID.
Cowan MJ; Yu J; Facchino J; Fraser-Browne C; Sanford U; Kawahara M; Dara J; Long-Boyle J; Oh J; Chan W; Chag S; Broderick L; Chellapandian D; Decaluwe H; Golski C; Hu D; Kuo CY; Miller HK; Petrovic A; Currier R; Hilton JF; Punwani D; Dvorak CC; Malech HL; McIvor RS; Puck JM
N Engl J Med; 2022 Dec; 387(25):2344-2355. PubMed ID: 36546626
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy outpaces haplo for SCID-X1.
Kohn DB
Blood; 2015 Jun; 125(23):3521-2. PubMed ID: 26045591
[TBL] [Abstract][Full Text] [Related]
23.
Rajawat YS; Humbert O; Cook SM; Radtke S; Pande D; Enstrom M; Wohlfahrt ME; Kiem HP
Hum Gene Ther; 2021 Jan; 32(1-2):113-127. PubMed ID: 32741228
[TBL] [Abstract][Full Text] [Related]
24. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
25. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
[TBL] [Abstract][Full Text] [Related]
26. Retroviral transduction of IL2RG into CD34(+) cells from X-linked severe combined immunodeficiency patients permits human T- and B-cell development in sheep chimeras.
Tsai EJ; Malech HL; Kirby MR; Hsu AP; Seidel NE; Porada CD; Zanjani ED; Bodine DM; Puck JM
Blood; 2002 Jul; 100(1):72-9. PubMed ID: 12070011
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy for primary immunodeficiencies: Part 1.
Cavazzana-Calvo M; Fischer A; Hacein-Bey-Abina S; Aiuti A
Curr Opin Immunol; 2012 Oct; 24(5):580-4. PubMed ID: 22981681
[TBL] [Abstract][Full Text] [Related]
30. Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene.
Zhan H; Gilmour K; Chan L; Farzaneh F; McNicol AM; Xu JH; Adams S; Fehse B; Veys P; Thrasher A; Gaspar H; Qasim W
PLoS One; 2013; 8(10):e77106. PubMed ID: 24204746
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
Reinhardt B; Habib O; Shaw KL; Garabedian E; Carbonaro-Sarracino DA; Terrazas D; Fernandez BC; De Oliveira S; Moore TB; Ikeda AK; Engel BC; Podsakoff GM; Hollis RP; Fernandes A; Jackson C; Shupien S; Mishra S; Davila A; Mottahedeh J; Vitomirov A; Meng W; Rosenfeld AM; Roche AM; Hokama P; Reddy S; Everett J; Wang X; Luning Prak ET; Cornetta K; Hershfield MS; Sokolic R; De Ravin SS; Malech HL; Bushman FD; Candotti F; Kohn DB
Blood; 2021 Oct; 138(15):1304-1316. PubMed ID: 33974038
[TBL] [Abstract][Full Text] [Related]
32. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
Cavazzana-Calvo M; Hacein-Bey S; de Saint Basile G; Gross F; Yvon E; Nusbaum P; Selz F; Hue C; Certain S; Casanova JL; Bousso P; Deist FL; Fischer A
Science; 2000 Apr; 288(5466):669-72. PubMed ID: 10784449
[TBL] [Abstract][Full Text] [Related]
34. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
35. Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency.
De Ravin SS; Liu S; Sweeney CL; Brault J; Whiting-Theobald N; Ma M; Liu T; Choi U; Lee J; O'Brien SA; Quackenbush P; Estwick T; Karra A; Docking E; Kwatemaa N; Guo S; Su L; Sun Z; Zhou S; Puck J; Cowan MJ; Notarangelo LD; Kang E; Malech HL; Wu X
Nat Commun; 2022 Jun; 13(1):3710. PubMed ID: 35764638
[TBL] [Abstract][Full Text] [Related]
36. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
Hacein-Bey-Abina S; Garrigue A; Wang GP; Soulier J; Lim A; Morillon E; Clappier E; Caccavelli L; Delabesse E; Beldjord K; Asnafi V; MacIntyre E; Dal Cortivo L; Radford I; Brousse N; Sigaux F; Moshous D; Hauer J; Borkhardt A; Belohradsky BH; Wintergerst U; Velez MC; Leiva L; Sorensen R; Wulffraat N; Blanche S; Bushman FD; Fischer A; Cavazzana-Calvo M
J Clin Invest; 2008 Sep; 118(9):3132-42. PubMed ID: 18688285
[TBL] [Abstract][Full Text] [Related]
37. Clinical and Laboratory Factors Affecting the Prognosis of Severe Combined Immunodeficiency.
Ozturk E; Catak MC; Kiykim A; Baser D; Bilgic Eltan S; Yalcin K; Kasap N; Nain E; Bulutoglu A; Akgun G; Can Y; Sefer AP; Babayeva R; Caki-Kilic S; Tezcan Karasu G; Yesilipek A; Ozen A; Karakoc-Aydiner E; Baris S
J Clin Immunol; 2022 Jul; 42(5):1036-1050. PubMed ID: 35451701
[TBL] [Abstract][Full Text] [Related]
38. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy.
Pike-Overzet K; van der Burg M; Wagemaker G; van Dongen JJ; Staal FJ
Mol Ther; 2007 Nov; 15(11):1910-6. PubMed ID: 17726455
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy.
André I; Simons L; Ma K; Moirangthem RD; Diana JS; Magrin E; Couzin C; Magnani A; Cavazzana M
Bone Marrow Transplant; 2019 Aug; 54(Suppl 2):749-755. PubMed ID: 31431705
[TBL] [Abstract][Full Text] [Related]
40. Case Report: A Novel IL2RG Frame-Restoring Rescue Mutation Mimics Early T Cell Engraftment Following Haploidentical Hematopoietic Stem Cell Transplantation in a Patient With X-SCID.
Steininger J; Leiss-Piller A; Geier CB; Rossmanith R; Elfeky R; Bra D; Pichler H; Lawitschka A; Zubarovskaya N; Artacker G; Matthes-Leodolter S; Eibl MM; Wolf HM
Front Immunol; 2021; 12():644687. PubMed ID: 33959125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
